A prospective Canadian gastroesophageal cancer database: What have we learned?

被引:1
|
作者
Purich, Kieran [1 ,2 ,3 ]
Skubleny, Daniel [2 ,3 ]
Ghosh, Sunita [3 ,4 ]
Bedard, Eric L. R. [2 ,3 ]
Stewart, Kenneth C. [2 ,3 ]
Johnson, Scott T. [2 ,3 ]
Haase, Erika [2 ,3 ]
McCall, Michael [2 ,3 ]
Schiller, Dan [2 ,3 ]
机构
[1] Walter C Mackenzie Hlth Sci Ctr, Dvorkin Lounge Mailroom 2G2,8440 112 St NW, Edmonton, AB T6G 2B7, Canada
[2] Univ Alberta, Dept Surg, Edmonton, AB, Canada
[3] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada
[4] Univ Alberta, Dept Oncol, Edmonton, AB, Canada
关键词
GASTRIC-CANCER; UNITED-STATES; SURVIVAL; ESOPHAGEAL; SURGERY; RISK; LAPAROSCOPY; PREDICTORS; MANAGEMENT; CARCINOMA;
D O I
10.1503/cjs.005122
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background:Minimal literature exists on outcomes for Canadian patients with gastroesophageal adenocarcinoma (GEA). The objective of our study was to establish a prospective clinical database to evaluate demographic characteristics, presentation and outcomes of patients with GEA. Methods:Patients diagnosed with GEA were recruited from Jan. 30, 2017, to Aug. 30, 2020. Data collected included demographic characteristics, presentation, treatment and survival. A multivariable model for overall survival in patients treated with curative intent was created using sex, lymph node status, resection margin status, age and tumour location as variables. Results:A total of 122 patients with adenocarcinoma of the stomach or gastroesophageal junction were included. Median age was 65 years (interquartile range [IQR] 59-74), 70% of patients were male and 26% were born outside of Canada. Median follow-up time was 14.5 (IQR 8.0-31.0) months. Following staging computed tomography scanning, 88% of patients were deemed to have potentially resectable disease. Eighty-one (76%) received staging laparoscopy and 74 (61%) were treated with curativeintent surgery. Forty-six (62%) patients had nodal metastases. The median number of nodes harvested was 22 (IQR 18-30). The R0 resection margin rate was 82%. The 3-year overall survival for patients who received curative-intent treatment was 63% and 38% for all patients. On multivariable analysis, female sex (hazard ratio [HR] 3.88, p = 0.01), positive nodal status (HR 3.58, p = 0.02), positive margins (HR 3.11, p = 0.03) and tumour location (HR 3.00, p = 0.03) were associated with decreased overall survival. Conclusion:Many of the patients with GEA in this study presented with advanced disease, and only 61% were offered curative-intent surgery. A prospective multicentre national GEA database is now being established.
引用
收藏
页码:E422 / E431
页数:10
相关论文
共 50 条
  • [11] Peripheral spondyloarthritis: What have we learned?
    Puche-Larrubia, Maria Angeles
    Lopez-Medina, Clementina
    Ziade, Nelly
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2023, 37 (03):
  • [12] What have we learned from BeSt?
    Allaart, Cornelia F.
    Markusse, Iris M.
    Lems, Willem F.
    CLINICAL IMMUNOLOGY, 2018, 186 : 74 - 78
  • [13] Liver cancer mortality over six decades in an epidemic area: what we have learned
    Chen, Jian-Guo
    Zhu, Jian
    Zhang, Yong-Hui
    Chen, Yong-Sheng
    Lu, Jian-Hua
    Zhu, Yuan-Rong
    Chen, Hai-Zhen
    Shen, Ai-Guo
    Wang, Gao-Ren
    Groopman, John D.
    Kensler, Thomas W.
    PEERJ, 2021, 9
  • [14] Service operations: what have we learned?
    Victorino, Liana
    Field, Joy M.
    Buell, Ryan W.
    Dixon, Michael J.
    Goldstein, Susan Meyer
    Menor, Larry J.
    Pullman, Madeleine E.
    Roth, Aleda V.
    Secchi, Enrico
    Zhang, Jie J.
    JOURNAL OF SERVICE MANAGEMENT, 2018, 29 (01) : 39 - 54
  • [15] Hepatic Retransplant What Have We Learned?
    Kitchens, William H.
    Yeh, Heidi
    Markmann, James F.
    CLINICS IN LIVER DISEASE, 2014, 18 (03) : 731 - +
  • [16] GWAS and autoimmunity: What have we learned and what next
    Gerussi, Alessio
    Soskic, Blagoje
    Asselta, Rosanna
    Invernizzi, Pietro
    Gershwin, Merrill E.
    JOURNAL OF AUTOIMMUNITY, 2022, 133
  • [17] What have we learned from cancer immunotherapy in the last 3 years?
    Paolo A Ascierto
    Francesco M Marincola
    Journal of Translational Medicine, 12
  • [18] Sex Hormones and Colorectal Cancer: What Have We Learned So Far?
    Lin, Jennifer H.
    Giovannucci, Edward
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (23): : 1746 - 1747
  • [19] What have we learned from cancer immunotherapy in the last 3 years?
    Ascierto, Paolo A.
    Marincola, Francesco M.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [20] Themed Issue on the Opioid Epidemic: What Have We Learned? Where Do We Go From Here?
    Benzon, Honorio T.
    Anderson, T. Anthony
    ANESTHESIA AND ANALGESIA, 2017, 125 (05) : 1435 - 1437